Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC)

被引：0

作者：

Motzer, Robert John

Barrios, Carlos H.

Kim, Tae Min

Falcon, Silvia

Cosgriff, Thomas

Harker, W. Graydon

Pittman, Kenneth B.

Sabbatini, Roberto

Rha, Sun Young

Flaig, Thomas W.

Page, Ray D.

Bavbek, Sevil E.

Beck, J. Thaddeus

Patel, Poulam M.

Schiff, Edward

Vaury, Alexandra

Niolat, Julie

Gogov, Sven

Anak, Ozlem

Knox, Jennifer

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] PUCRS Sch Med, Porto Alegre, RS, Brazil

[3] Seoul Natl Univ Hosp, Seoul 110744, South Korea

[4] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru

[5] Hematol & Oncol Specialists, Metairie, LA USA

[6] Utah Canc Specialists, Salt Lake City, UT USA

[7] Queen Elizabeth Hosp, Adelaide, SA, Australia

[8] Azienda Osped Univ, Modena, Italy

[9] Yonsei Canc Ctr, Seoul, South Korea

[10] Univ Colorado, Sch Med, Aurora, CO USA

[11] Ctr Canc & Blood Disorders, Ft Worth, TX USA

[12] Amer Hosp, Istanbul, Turkey

[13] Highlands Oncol Grp, Fayetteville, AR USA

[14] Univ Nottingham, Nottingham NG7 2RD, England

[15] Novartis Pharmaceut, Novartis Oncol, Florham Pk, NJ USA

[16] Novartis Pharma SAS, Novartis Oncol, Rueil Malmaison, France

[17] Novartis Pharma AG, Basel, Switzerland

[18] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4504

引用

页数：1

共 50 条

[1] Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
Motzer, Robert J.
Barrios, Carlos H.
Kim, Tae Min
Falcon, Silvia
Cosgriff, Thomas
Harker, W. Graydon
Srimuninnimit, Vichien
Pittman, Ken
Sabbatini, Roberto
Rha, Sun Young
Flaig, Thomas W.
Page, Ray
Bavbek, Sevil
Beck, J. Thaddeus
Patel, Poulam
Cheung, Foon-yiu
Yadav, Sunil
Schiff, Edward M.
Wang, Xufang
Niolat, Julie
Sellami, Dalila
Anak, Oezlem
Knox, Jennifer J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2766 - +
[2] First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC)
Knox, J. J.
Kay, A. C.
Schiff, E.
Hollaender, N.
Rouyrre, N.
Ravaud, A.
Motzer, R. J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[3] RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC)
Motzer, Robert
Alyasova, Anna
Ye, Dingwei
Karpenko, Andrey
Li, Hanzhong
Alekseev, Boris Y.
Xie, Liping
Kurteva, Galina Petrova
Kowalyszyn, Ruben Dario
Neron, Yeni
Cosgriff, Thomas
Collins, LaTonya
Brechenmacher, Thomas
Segal, Scott
Morgan, Liza M.
Yang, Lin
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] RECORD-4: a multicenter phase 2 trial of second-line everolimus (EVE) in patients with metastatic renal cell carcinoma (mRCC)
Cosgriff, Thomas
Alyasova, Anna
Ye, Dingwei
Xie, Liping
Kurteva, Galina
Kowalyszyn, Ruben
Neron, Yeni
Collins, Latonya
Brechenmacher, Thomas
Lin, Chinjune
Morgan, Liza
Yang, Lin
Motzer, Robert
[J]. BJU INTERNATIONAL, 2015, 116 : 6 - 7
[5] Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma
Chen, Chi-Chang
Hess, Gregory P.
Liu, Zhimei
Gesme, Dean H.
Agarwala, Sanjiv S.
Garay, Carlos C.
Hill, Jerrold W.
Guo, Amy
[J]. CLINICAL GENITOURINARY CANCER, 2012, 10 (04) : 256 - 261
[6] Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by Sunitinib versus first-line Sunitinib Followed by Everolimus in metastatic RCC (mRCC)
Knox, Jennifer J.
Barrios, Carlos H.
Kim, Tae Min
Cosgriff, Thomas
Srimuninnimit, Vichien
Pittman, Ken
Sabbatini, Roberto
Rha, Sun Young
Flaig, Thomas W.
Page, Ray D.
Beck, J. Thaddeus
Cheung, Foon-Yiu
Yadav, Sunil
Patel, Poulam
Geoffrois, Lionel
Schiff, Edward M.
Niolat, Julie
Berkowitz, Noah
Voi, Maurizio
Motzer, Robert J.
[J]. BJU INTERNATIONAL, 2015, 116 : 15 - 15
[7] Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).
Knox, Jennifer J.
Barrios, Carlos H.
Kim, Tae Min
Cosgriff, Thomas
Srimuninnimit, Vichien
Pittman, Kenneth B.
Sabbatini, Roberto
Rha, Sun Young
Flaig, Thomas W.
Page, Ray D.
Beck, J. Thaddeus
Cheung, Foon Yiu
Yadav, Sunil
Patel, Poulam M.
Geoffrois, Lionnel
Schiff, Edward
Niolat, Julie
Berkowitz, Noah
Voi, Maurizio
Motzer, Robert
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
Sun, Maxine
Larcher, Alessandro
Karakiewicz, Pierre I.
[J]. INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2014, 7 : 401 - 407
[9] Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
Knox, J. J.
Barrios, C. H.
Kim, T. M.
Cosgriff, T.
Srimuninnimit, V.
Pittman, K.
Sabbatini, R.
Rha, S. Y.
Flaig, T. W.
Page, R. D.
Beck, J. T.
Cheung, F.
Yadav, S.
Patel, P.
Geoffrois, L.
Niolat, J.
Berkowitz, N.
Marker, M.
Chen, D.
Motzer, R. J.
[J]. ANNALS OF ONCOLOGY, 2017, 28 (06) : 1339 - 1345
[10] SECOND-LINE TREATMENT WITH PAZOPANIB FOLLOWING FIRST-LINE SUNITINIB OR BEVACIZUMAB IN ADVANCED RENAL CELL CARCINOMA: PRELIMINARY RESULTS OF A PHASE II TRIAL
Hainsworth, J.
Spigel, D. R.
Webb, C.
Daniel, D.
Friedman, E.
Burris, H.
[J]. ANNALS OF ONCOLOGY, 2010, 21 : 285 - 285

← 1 2 3 4 5 →